Literature DB >> 17285785

Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.

Javier F Aduen1, David A Zisman, Syed I Mobin, Carla Venegas, Francisco Alvarez, Michelle Biewend, Howard I Jolles, Cesar A Keller.   

Abstract

OBJECTIVE: To examine the frequency and spectrum of diseases associated with isolated reduction in the diffusing capacity of lung for carbon monoxide (D(Lco)). PATIENTS AND METHODS: We retrospectively identified all potentially dyspneic patients who had pulmonary function tests (PFTs) performed at the Mayo Clinic in Jacksonville, Fla, between January 1, 1990, and June 30, 2000, that showed reduced D(Lco) (< 70% of predicted), normal lung volumes (total lung capacity and residual volume > 80% and < 120% of predicted, respectively), and airflow variables (forced expiratory volume in 1 second and forced vital capacity values > 80% of predicted and forced expiratory volume in 1 second/forced vital capacity ratio > 70% of predicted). Only patients who had also undergone chest computed tomography (CT) and echocardiography within 1 month of PFTs were studied.
RESULTS: Of the 38,095 patients who underwent PFTs during the study period, 179 (0.47%; 95% confidence interval [CI], 0.40%-0.54%) had isolated D(Lco) abnormalities. The 27 patients (15.1%; 95% CI, 10.2%-21.2%) who had also undergone chest CT and echocardiography within 1 month of PFTs form the study cohort reported herein. Their mean D(Lco) was 50% +/- 15% (95% CI, 45%-56%) with average normal pulse oxygen saturation at rest and mild hypoxemia with activity. Thirteen of the 27 patients (48%; 95% CI, 28.7%-68.1%) had underlying emphysema evident on CT. Eleven of these 13 patients had emphysema associated with a restrictive lung process. The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings. Six patients with combined emphysema and idiopathic pulmonary fibrosis accounted for the largest percentage (22%) of patients with Isolated D(Lco) reduction. The mean +/- SD smoking history of the 27 patients in the study cohort was 36 +/- 33 pack-years (range, 0-116 pack-years).
CONCLUSION: Dyspneic patients with respiratory symptoms and normal lung volumes and airflows associated with Isolated reduction in D(Lco) should be evaluated for underlying diseases such as emphysema, with or without a concomitant restrictive process, and pulmonary vascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17285785     DOI: 10.4065/82.1.48

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  13 in total

1.  Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  David A Zisman; David J Ross; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Arun S Karlamangla
Journal:  Respir Med       Date:  2007-07-02       Impact factor: 3.415

Review 2.  Current clinical management of pulmonary arterial hypertension.

Authors:  Roham T Zamanian; Kristina T Kudelko; Yon K Sung; Vinicio de Jesus Perez; Juliana Liu; Edda Spiekerkoetter
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

Review 4.  Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.

Authors:  Patrick D W Kiely; Felix Chua
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

Review 5.  Normal expiratory flow rate and lung volumes in patients with combined emphysema and interstitial lung disease: a case series and literature review.

Authors:  Karen L Heathcote; Donald W Cockcroft; Derek A Fladeland; Mark E Fenton
Journal:  Can Respir J       Date:  2011 Sep-Oct       Impact factor: 2.409

Review 6.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

Review 7.  Diffusing capacity.

Authors:  Matthew J Hegewald
Journal:  Clin Rev Allergy Immunol       Date:  2009-03-31       Impact factor: 8.667

8.  Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma.

Authors:  Mark J Hamblin; Maureen R Horton
Journal:  Pulm Med       Date:  2011-06-04

9.  Combined Pulmonary Fibrosis and Emphysema Syndrome: A New Phenotype within the Spectrum of Smoking-Related Interstitial Lung Disease.

Authors:  Karina Portillo; Josep Morera
Journal:  Pulm Med       Date:  2012-02-09

10.  Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV.

Authors:  Amanda K Jan; Julia V Moore; Richard J Wang; Maggie Mcging; Carly K Farr; Daniela Moisi; Marlena Hartman-Filson; Robert Kerruish; Diane Jeon; Eula Lewis; Kristina Crothers; Michael M Lederman; Peter W Hunt; Laurence Huang
Journal:  AIDS       Date:  2021-06-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.